Showing 1871-1880 of 6977 results for "".
Aubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?Why Online Citations and NAPs are So Important to SEO
https://practicaldermatology.com/topics/practice-management/why-online-citations-and-naps-are-so-important-to-seo/18790/Google uses local citations to determine a site ranking in local search results. You can optimize citations and NAPs (name, address, phone) to improve your local listing. Find out in this educational video from Ekwa.com.Laser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.AAD Highlights; Cyndi Lauper on Psoriasis; Qilib and More
https://practicaldermatology.com/topics/psoriasis/dermwiretv-aad-highlights-cyndi-lauper-on-psoriasis-qilib-and-more/18806/Highlights from the educational sessions at the AAD Annual Meeting; Cyndi Lauper Says there's more to Psoriasis. Galderma Launches qilib and more from the exhibit hall at AAD. Plus SkinCeuticals opens Male Aesthetics Center in DC.Restylane Silk Launches; Xeljanz to FDA
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-restylane-silk-launches-xeljanz-to-fda/18970/This edition of DermWireTV covers the launch of Restylane Silk from Galderma for the treatment of lips and FDA acceptance of the NDA for Pfizer's Xeljanz (tofacitinib) for adults with psoriasis. Plus, new data from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) show incrAllergan Board Rejects Latest Valeant Bid; Topical Jublia Approved for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dwtv-6-12/19122/Allergan's board rejects the latest merger proposal from Valeant and the FDA approves topical Jublia for onychomycosis. LEarn about these developments and hear from the AMA's new president in this edition of DermWireTV.Vitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of its